Efaproxiral

Drug Profile

Efaproxiral

Alternative Names: EFAPROXYN; GSJ 61; JP 4; KDD 86; REVAPROXYN; RS 4; RSR 13

Latest Information Update: 25 Jun 2007

Price : $50

At a glance

  • Originator Center for Innovative Technology
  • Developer Allos Therapeutics
  • Class Aniline compounds; Antineoplastics; Propionic acids; Radiosensitisers; Small molecules
  • Mechanism of Action Haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer

Highest Development Phases

  • Discontinued Angina pectoris; Brain cancer; Cervical cancer; Glioblastoma; Glioma; Myocardial infarction; Non-small cell lung cancer; Stroke

Most Recent Events

  • 19 Jun 2007 Discontinued - Phase-II for Non-small cell lung cancer in Canada (IV)
  • 19 Jun 2007 Discontinued - Phase-I/II for Non-small cell lung cancer in USA (IV)
  • 19 Jun 2007 Discontinued - Phase-II for Glioblastoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top